United Laboratories International Holdings Ltd

03933

Company Profile

  • Business description

    United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. The majority of the company's sales are generated in China, followed by Europe, India and other countries.

  • Contact

    No. 6 Fuk Wang Street
    Yuen Long Industrial Estate
    New Territories
    Hong Kong
    HKG

    T: +852 26871033

    http://www.tul.com.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    17,000

Stocks News & Analysis

stocks

ASX reporting season wrap: BHP, banks, CSL bloodbath and more

A round up of notable stories and reactions as ASX earnings season continues.
stocks

Stock showdown: How do ASX healthcare giants compare on key investing criteria?

Our healthcare analyst Shane Ponraj helps me compare the moatiness and growth prospects of two sector heavyweights.
stocks

Peak profit for ASX listed insurer

Simplification plan complete, organic growth now the focus.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,234.3055.70-0.60%
CAC 407,969.6931.400.40%
DAX 4024,363.0969.750.29%
Dow JONES (US)45,631.74846.241.89%
FTSE 1009,321.4012.200.13%
HKSE25,339.14234.530.93%
NASDAQ21,496.54396.221.88%
Nikkei 22542,633.2923.120.05%
NZX 50 Index13,042.76151.31-1.15%
S&P 5006,466.9196.741.52%
S&P/ASX 2008,967.4057.00-0.63%
SSE Composite Index3,825.7654.661.45%

Market Movers